These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14689815)

  • 1. A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey.
    Späth HM; Charavel M; Morelle M; Carrere MO
    Pharm World Sci; 2003 Dec; 25(6):269-75. PubMed ID: 14689815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do economic evaluations have a role in decision-making in Medicine Management Committees? A qualitative study.
    Chen LC; Ashcroft DM; Elliott RA
    Pharm World Sci; 2007 Dec; 29(6):661-70. PubMed ID: 17566869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluations of health technologies in Dutch healthcare decision-making: a qualitative study of the current and potential use, barriers, and facilitators.
    Roseboom KJ; van Dongen JM; Tompa E; van Tulder MW; Bosmans JE
    BMC Health Serv Res; 2017 Jan; 17(1):89. PubMed ID: 28126005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of clinical, patient-reported outcome and medico-economic studies in the public hospital drug formulary decision-making process: results of a European survey.
    Haslé-Pham E; Arnould B; Späth HM; Follet A; Duru G; Marquis P;
    Health Policy; 2005 Feb; 71(2):205-12. PubMed ID: 15607382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of centrally developed pharmacoeconomic assessments for local formulary decisions.
    Tordoff JM; Murphy JE; Norris PT; Reith DM
    Am J Health Syst Pharm; 2006 Sep; 63(17):1613-8. PubMed ID: 16914631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of pharmacoeconomic data in formulary selection.
    Hatoum HT; Freeman RA
    Top Hosp Pharm Manage; 1994 Jan; 13(4):47-53. PubMed ID: 10130683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the decision making process of selection of medicines in the private sector in South Africa - lessons for low-middle income countries.
    Perumal-Pillay VA; Suleman F
    J Pharm Policy Pract; 2020; 13():17. PubMed ID: 32477570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Application of Pharmacoeconomic Evaluations in Medicines Management by Hospital Pharmacists in Nigeria: A Cross-Sectional Survey.
    Oamen TE; Osemene KP; Ihekoronye RM
    Hosp Top; 2023; 101(3):165-174. PubMed ID: 34821536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barriers to implementing pharmacoeconomics: interview study.
    Alefan Q; Hamdouni E; Alhamad H; Mukattash T; Rascati K
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):93-104. PubMed ID: 32394752
    [No Abstract]   [Full Text] [Related]  

  • 10. Application of pharmacoeconomics to formulary decision making in managed care organizations.
    Suh DC; Okpara IR; Agnese WB; Toscani M
    Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Old and new long stay patients in French psychiatric institutions: results from a national random survey with two-year follow-up].
    Chapireau F
    Encephale; 2005; 31(4 Pt 1):466-76. PubMed ID: 16389714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making.
    Drummond M; Brown R; Fendrick AM; Fullerton P; Neumann P; Taylor R; Barbieri M;
    Value Health; 2003; 6(4):407-16. PubMed ID: 12859580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacoeconomics].
    Shiragami M
    Yakugaku Zasshi; 2003 Mar; 123(3):133-42. PubMed ID: 12693013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovative medical devices and hospital decision making: a study comparing the views of hospital pharmacists and physicians.
    Billaux M; Borget I; Prognon P; Pineau J; Martelli N
    Aust Health Rev; 2016 Jun; 40(3):257-261. PubMed ID: 26342894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of pharmacoeconomic data in making hospital formulary decisions.
    Odedina FT; Sullivan J; Nash R; Clemmons CD
    Am J Health Syst Pharm; 2002 Aug; 59(15):1441-4. PubMed ID: 12166044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Funding and access to high cost medicines in public hospitals in Australia: decision-makers' perspectives.
    Gallego G; Taylor SJ; Brien JA
    Health Policy; 2009 Sep; 92(1):27-34. PubMed ID: 19269709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.